619 research outputs found
A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus
No full textWH Wilson TangSection of Heart Failure and Cardiac Transplantation Medicine, Department of Cardiovascular Medicine, the Cleveland Clinic, Cleveland, OH, USAAbstract: Anti-adrenergic therapy has been widely accepted as an important therapeutic intervention in patients with chronic heart failure. However, there has been continuing controversy regarding the risks and clinical significance of metabolic effects of different anti-adrenergic drugs. This review summarizes what has been learned from clinical trial evidence regarding the benefits of anti-adrenergic drugs in diabetic patients with chronic heart failure.Keywords: diabetes mellitus, congestive heart failure, anti-adrenergic drugs, carvedilo
sj-pdf-3-tmj-10.1177_03008916221133136 – Supplemental material for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options
No full textsj-pdf-3-tmj-10.1177_03008916221133136 for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options by Spencer H Shao, Brian Allen, Jessica Clement, Gina Chung, Jingjing Gao, Earl Hubbell, Minetta C Liu, Charles Swanton, WH Wilson Tang, Habte Yimer and Mohan Tummala in Tumori Journal</p
sj-pdf-1-tmj-10.1177_03008916221133136 – Supplemental material for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options
No full textSupplemental material, sj-pdf-1-tmj-10.1177_03008916221133136 for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options by Spencer H Shao, Brian Allen, Jessica Clement, Gina Chung, Jingjing Gao, Earl Hubbell, Minetta C Liu, Charles Swanton, WH Wilson Tang, Habte Yimer and Mohan Tummala in Tumori Journal</p
sj-xlsx-6-tmj-10.1177_03008916221133136 – Supplemental material for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options
No full textsj-xlsx-6-tmj-10.1177_03008916221133136 for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options by Spencer H Shao, Brian Allen, Jessica Clement, Gina Chung, Jingjing Gao, Earl Hubbell, Minetta C Liu, Charles Swanton, WH Wilson Tang, Habte Yimer and Mohan Tummala in Tumori Journal</p
sj-pdf-7-tmj-10.1177_03008916221133136 – Supplemental material for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options
No full textSupplemental material, sj-pdf-7-tmj-10.1177_03008916221133136 for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options by Spencer H Shao, Brian Allen, Jessica Clement, Gina Chung, Jingjing Gao, Earl Hubbell, Minetta C Liu, Charles Swanton, WH Wilson Tang, Habte Yimer and Mohan Tummala in Tumori Journal</p
sj-pdf-4-tmj-10.1177_03008916221133136 – Supplemental material for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options
No full textsj-pdf-4-tmj-10.1177_03008916221133136 for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options by Spencer H Shao, Brian Allen, Jessica Clement, Gina Chung, Jingjing Gao, Earl Hubbell, Minetta C Liu, Charles Swanton, WH Wilson Tang, Habte Yimer and Mohan Tummala in Tumori Journal</p
sj-xlsx-5-tmj-10.1177_03008916221133136 – Supplemental material for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options
No full textsj-xlsx-5-tmj-10.1177_03008916221133136 for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options by Spencer H Shao, Brian Allen, Jessica Clement, Gina Chung, Jingjing Gao, Earl Hubbell, Minetta C Liu, Charles Swanton, WH Wilson Tang, Habte Yimer and Mohan Tummala in Tumori Journal</p
sj-pdf-2-tmj-10.1177_03008916221133136 – Supplemental material for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options
No full textsj-pdf-2-tmj-10.1177_03008916221133136 for Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options by Spencer H Shao, Brian Allen, Jessica Clement, Gina Chung, Jingjing Gao, Earl Hubbell, Minetta C Liu, Charles Swanton, WH Wilson Tang, Habte Yimer and Mohan Tummala in Tumori Journal</p
Rising plasma nociceptin level during development of HCC: A case report
No full textAIM: Although liver cirrhosis is a predisposing factor for hepatocellular carcinoma (HCC), relatively few reports are available on HCC in primary biliary cirrhosis. High plasma nociceptin (N/OFQ) level has been shown in Wilson disease and in patients with acute and chronic pain.
METHODS: We report a follow-up case of HCC, which developed in a patient with primary biliary cirrhosis. The tumor appeared 18 years after the diagnosis of PBC and led to death within two years. Alfa fetoprotein and serum nociceptin levels were monitored before and during the development of HCC. Nociceptin content was also measured in the tumor tissue.
RESULTS: The importance and the curiosity of the presented case was the novel finding of the progressive elevation of plasma nociceptin level up to 17-fold (172 pg/mL) above the baseline (9.2 +/- 1.8 pg/mL) parallel with the elevation of alpha fetoprotein (from 13 ng/mL up to 3 480 ng/mL) during tumor development. Nociceptin content was more than 15-fold higher in the neoplastic tissue (0.16 pg/mg) than that in the tumor-free liver tissue samples (0.01 pg/mg) taken during the autopsy.
CONCLUSION: Results are in concordance with our previous observation that a very high plasma nociceptin level may be considered as an indicator for hepatocellular carcinoma
Cardiovascular Volume Reserve in Patients with Heart Failure and Reduced Ejection Fraction
No full textThis study aimed to investigate the relationship between intravascular volume and intracardiac filling pressures in stable HF patients with reduced ejection fraction (HFrEF). A total of 40 HFrEF patients (LVEF 36 +/- 10%) (10 subjects with a pulmonary artery catheter) underwent intravascular volume expansion with 1 L hydroxyl-ethyl-starch over 3 h with coinciding intravascular volume measurements (technetium (99 tc)-labeled red blood cell technique). Intravascular blood volume increased from 5.0 +/- 1.0 L to 5.7 +/- 1.0 L (p < 0.0001). No change in clinical status, echocardiographic indices, or cardiac filling pressures was noticed. Invasively measured right atrial pressure and pulmonary arterial wedge pressure increased significantly immediately after start of infusion (4 +/- 2 mmHg to 8 +/- 4 mmHg; p = 0.01 and 10 +/- 3 mmHg to 15 +/- 6 mmHg; p = 0.01, respectively), decreased afterwards, and remained stable for 3 h (6 +/- 2 mmHg and 14 +/- 4 mmHg, respectively). The accuracy of cardiac filling pressure estimates to predict intravascular volume expansion was low (all AUC < 0.65).P.N is supported by The Frans Van de Werf Fund for Clinical Cardiovascular Research. P.N., P.M., and W.M. are researchers for the Limburg Clinical Research Program (LCRP) UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk (LSM), Hasselt University, Ziekenhuis Oost-Limburg, and Jessa Hospital. P.N. and M.D. are supported by a research grant provided by Vision4Life-Sciences.Nijst, P (reprint author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium, Hasselt Univ, Doctoral Sch Med & Life Sci, Diepenbeek, Belgium.
[email protected]
- …
